FMP
CORT icon

Financial Management Professionals’s Corcept Therapeutics CORT Stock Holding History

Financial Management Professionals’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,992
Closed -$51K – 935
2022
Q3 		$51K Hold
1,992
– – 0.01% 217
2022
Q2 		$47K Buy
+1,992
New +$43.4K 0.01% 230

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Financial Management Professionals's CORT Position: Q4 2022 in Review

Financial Management Professionals sold out of Corcept Therapeutics (CORT) in Q4 2022, closing a stake of 1,992 shares — an estimated $51K sold.

Financial Management Professionals first reported a position in CORT in Q2 2022 and held it in 2 quarters. The position peaked at $51K in Q3 2022. 241 funds tracked by Wall St. Rank hold CORT as of Q4 2022.

  • Financial Management Professionals reported no remaining Corcept Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Financial Management Professionals sold 1,992 Corcept Therapeutics shares in Q4 2022, an estimated $51K.
  • Financial Management Professionals first reported a position in Corcept Therapeutics in Q2 2022 and held it in 2 quarters.
  • Financial Management Professionals's Corcept Therapeutics position peaked at $51K in Q3 2022.
  • 241 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2022.

Based on Financial Management Professionals's 13F filing for Q4 2022, filed 11 Jan 2023.